Partnering with @sanofi will help accelerate clinical development of VXB-241 and next generation products. This is a fantastic outcome for the Vicebio platform and for patients suffering these viral respiratory infections.

Vicebio was created by @medicxi to develop next-generation vaccines for respiratory viruses, utilising its proprietary Molecular Clamp technology. The lead asset, VXB-241, is a bivalent vaccine targeting RSV and hMPV, currently in Phase 1 clinical development.

Congratulations to Giovanni Mariggi (@GMariggi), who led our involvement in Vicebio from inception to exit, to the CEO Emmanuel Hanon and the entire Vicebio team for executing and delivering on Medicxi’s original product vision 🎯.

Thrilled to announce that @medicxi portfolio company Vicebio has entered into an exclusive agreement to be acquired by @sanofi for $1.6B, including an upfront payment of $1.15B 🚀🚀.

Rhinovirus infections account for >45% of COPD exacerbations and are associated with poorer outcomes for patients with COPD. Vapendavir has potent activity against 97% of rhinoviruses, and could help prevent the devastating consequences of rhinovirus-mediated COPD exacerbations.

In this placebo-controlled study, treatment with vapendavir was well tolerated, led to faster reduction in viral load and a shorter overall course of illness with fewer adverse and severe adverse respiratory events versus placebo.

Congratulations to the Altesa Biosciences team on reporting positive Phase 2 data for vapendavir in a Rhinovirus challenge study in patients with COPD.

Medicxi is joined by other new investors OrbiMed, HBM Healthcare Investments and Sanofi Ventures, with participation of current insiders . Funding will support completion of Phase 2 development, with a clear path towards Phase 3 and market authorization.

Curevo is developing Amezosvatein, to address critical unmet needs in shingles vaccination. In Phase 2, Amezosvatein demonstrated competitive efficacy and potential for superior tolerability versus Shingrix, thanks to Curevo’s proprietary adjuvant technology.

Excited to announce that Medicxi has led Curevo Vaccine’s $110M Series B financing. As part of this financing, Giovanni Mariggi will join the board of directors, alongside vaccine industry leaders Moncef Slaoui and Tal Zaks .

Kaerus will advance KER-0193 into Phase 2 proof-of-concept study later this year, moving one step closer to providing a safe and efficacious therapy to patients with FXS.

KER-0193 was safe and well tolerated in 56 healthy volunteers, with positive pharmacodynamic effects confirmed in translationally relevant parameters by pharmaco-EEG.

Congratulations to Kaerus Bioscience for successfully completing Phase 1 development for KER-0193, a novel BK channel modulator for Fragile X syndrome (FXS).

This marks Alys' first clinical study following its $100M seed financing from @medicxi , with multiple proof-of-concept readouts expected across multiple indications in immune-dermatology by 2027.

ALY-101 is the first clinical candidate from Alys' collaboration with the RNA Institute at UMass Chan Medical School, pioneering RNA-based therapies to target the root causes of immune-mediated skin diseases.

🚀 Congratulations to Alys Pharmaceuticals on advancing its first intradermally administered siRNA for immune-dermatology into the clinic!. The Phase 2a will evaluate the safety & efficacy of ALY-101, a JAK1-targeted siRNA in patients with alopecia areata.

Ottimo's Series A is led by OrbiMed, Avoro Capital and Samsara BioCapital with participation from RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences, The Invus Group and Medicxi.

Congratulations to Ottimo Pharma on the completion of its Series A!. Ottimo has raised over $140M to supercharge development of it’s first-in-class bifunctional medicines in oncology . An IND filing for its lead asset, Jankistomig, is planned for late 2025.

Ottimo is developing Jankistomig, a PD1/VEGFR2 bifunctional antibody, designed to advance the field of cancer immunotherapy by targeting both immune checkpoint inhibition and angiogenesis. Jankistomig is in late preclinical development, and is expected to enter the clinic in 2025.

We are excited to announce the launch of Ottimo Pharma, with the appointment of David Epstein as Chair & Chief Executive Officer. He is joined by Mehdi Shahidi, Head of Development & Chief Medical Officer, and James Sabry as Vice Chair of the Board.